Janux Therapeutics Inc. has nominated a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (BMS). The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr (Tumor Activated T Cell Engager) platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types. The milestone triggers a payment to Janux.
Protein arginine methyltransferase 1 (PRMT1) is a key enzyme that catalyzes post-translational arginine methylation, thereby regulating diverse cellular processes, including gene transcription, RNA splicing, signal transduction, and DNA damage repair. As a central epigenetic and signaling regulator, PRMT1 plays a critical role in coordinating cellular proliferation, differentiation, and survival.
Frontier Medicines Corp. has granted LG Chem Ltd. an exclusive worldwide license to develop and commercialize FMC-220, a covalent p53 Y220C activator, outside of Greater China. Frontier retains ownership and full control in Greater China.
Ernexa Therapeutics Inc. is advancing its lead program, ERNA-101, toward an IND submission in the third quarter of this year and the initiation of a first-in-human trial in the fourth quarter for the treatment of platinum-resistant ovarian cancer.
Fosun Pharmaceutical (Group) Co. Ltd. has received the approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of FXB-0871 (TEV-56278) for the treatment of locally advanced or metastatic solid tumors.
A new pan-cancer study has uncovered a shared vulnerability across multiple aggressive cancers and sheds light on the role that BRCA1-associated protein 1 (BAP1) plays in recognizing DNA damage. Researchers from Duke-National University of Singapore (NUS) Medical School in Singapore discovered that the loss of BAP1 – a mutation found in mesothelioma, cholangiocarcinoma, renal cell carcinoma and uveal melanoma – creates a specific defect in how cancer cells recognize and repair DNA damage.
Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.
Shanghai Meiyue Biotech Development Co. Ltd. has disclosed new molecular glue degraders comprising an E3 ubiquitin-protein ligase binding agents coupled to proto-oncogene Vav (VAV1) acting as VAV1 degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has discovered new tricyclic compounds acting as cyclin-dependent kinase 12 (CDK12)/cyclin k inhibitors reported to be useful for the treatment of cancer.
Ring finger protein 4 (RNF4) is a SUMO-targeted ubiquitin ligase that modulates proteins involved in cancer progression. Researchers from Chongqing Medical University and collaborators reported the development and preclinical characterization of [I], the first RNF4-targeting PROTAC degrader for the treatment of hepatocellular carcinoma (HCC).
RSS
